

## **Supplementary Information for**

The phosphorylation of AMPK $\beta$ 1 is critical for increasing autophagy and maintaining mitochondrial homeostasis in response to fatty acids

Eric M. Desjardins<sup>1,2</sup>, Brennan K. Smith<sup>1,2</sup>, Emily A. Day<sup>1,2,&</sup>, Serge Ducommun<sup>3,#</sup>, Matthew J. Sanders<sup>3</sup>, Joshua P. Nederveen<sup>1,4</sup>, Rebecca J. Ford<sup>1,2</sup>, Stephen L. Pinkosky<sup>1,2</sup>, Logan K. Townsend<sup>1,2</sup>, Robert M. Gutgesell<sup>1,2</sup>, Rachel Lu<sup>1,2</sup>, Kei Sakamoto<sup>3,5\*</sup> and Gregory R. Steinberg<sup>1,2,6\*</sup>

<sup>1</sup>Centre for Metabolism Obesity and Diabetes Research, McMaster University, Hamilton, Canada <sup>2</sup>Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Canada

<sup>3</sup>Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland

<sup>4</sup>Department of Pediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Canada <sup>5</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark

<sup>6</sup>Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada <sup>&</sup>Current address: School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, Ireland

#Current address: Department of Physiology and Pharmacology, Karolinska Institute, Solna, Sweden

\*Correspondence to Gregory R. Steinberg or Kei Sakamoto

Centre for Metabolism, Obesity and Diabetes Research, McMaster University, 1280 Main St. West, Hamilton, Ontario, L8N 3Z5, Canada, Tel: 905.525.9140 ext. 21691

Email: gsteinberg@mcmaster.ca


Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen

2200, Denmark


Email: kei.sakamoto@sund.ku.dk

## This PDF file includes:


Figures S1 to S5 SI References




Supplemental Figure 1. Regulation of recombinant AMPKα2β1γ1 WT and S108A mutant. (A) Recombinant human AMPKα2β1γ1 wild-type (WT) and AMPKα2β1(S108A)γ1 mutant was expressed and purified as described previously (1), resolved by SDS-PAGE and stained with Coomassie blue (upper image) or subjected to immunoblot analysis (lower images) with the indicated antibodies. (B-C) AMPK activity of bacterially expressed recombinant  $\alpha$ 2β1γ1 WT or S108A mutant in the presence of increasing concentrations of AMP (B) or A769662 (C) was measured as described (1). Results are presented as fold activation compared to no activator control (average ± SEM of at least 3 independent experiments). (D) Unphosphorylated AMPKα2β1γ1 WT and S108A was incubated with varying concentrations of recombinant CaMKKβ and the phosphorylation of AMPKα Thr172 was determined by immunoblot analysis. The bands were quantified and normalized to AMPKβ1 expression and displayed in the graph above a representative blot (average ± SEM of at least 3 independent experiments). (E) Phosphorylated AMPKα2β1γ1 WT and S108A was incubated with varying concentrations of recombinant protein phosphatase 2Cα (PP2C) and phosphorylation of AMPKα Thr172 was determined by immunoblot analysis. The percentage of pThr172 was determined relative to phosphorylated AMPKα2β1γ1 WT or S108A in the absence of PP2Cα and a graph is displayed above a representative blot (average ± SEM of at least 3 independent experiments).




Supplemental Figure 2. S108A knock-in targeting strategy. A schematic illustrating the targeting strategy used to generate C57BL/6NTac Prkab1/AMPKβ1 S108A knock-in (KI) mouse model. The targeting strategy is based on NCBI transcript NM\_031869.2. Exons and FRT recombination sites are represented by dark grey boxes and triangles, respectively. The amino acid to be exchanged (Ser108) is encoded by nucleotides located at the exon-intron boundary. There was a risk that changes in the nucleotide sequence might interfere with splicing of the transcript (leading to a hypomorphic effect). Therefore, we designed the targeting vector to achieve the S108A mutation with two options (KI-PM allele 1 or KI-PM allele 2). The constitutive KI-PM allele 1 is obtained after Cre-mediated removal of exons 2 to 7 (containing the joint exon 2 and 3) and of the NeoR selection marker. The KI-PM allele 1 strategy resulted in normal expression of the mutant (S108A) protein in tissues studied as demonstrated in Figure 1B and C.



Supplemental Figure 3. S108A-KI mice have no alterations in basal metabolic parameters on a chow or high-fat diet. (A) Immunoblots of AMPK subunits, phosphorylation, and downstream markers of activation in the same liver and Quad samples from Figure 1A (CD: chow diet-fed). (B-G) Body weight (B), energy expenditure (C), 6 hr fasted blood glucose (D), caloric consumption (E), activity levels (F), and respiratory exchange ratio (R.E.R.) (G) in WT and S108A-KI mice fed a control chow diet (CD) or high-fat diet (HFD). (H) Intraperitoneal glucose tolerance test (2.0 g/kg) and calculated area under the curve (GTT AUC) in WT and S108A-KI mice fed a control chow diet. (I) Representative immunoblots and densitometrical analysis of OXPHOS complexes 2-5 of WT and S108A-KI mice fed a control chow diet. Data are means ± S.E.M. with p-values reported in the graphs. Black bars signify main effects for diet. Statistical significance was accepted at p < 0.05 and determined via two-way ANOVA. White circles are individual mice per group.



Supplemental Figure 4. S108A-KI mice have an attenuated response in lipid oxidation to exogenous lipids, but have a normal response to AlCAR in vivo. Food intake during 2 hr refeed (A) prior to, and activity levels over 6 hrs (B) following, an oral gavage of saline or Intralipid (10 mL/kg) in chow diet-fed WT and S108A-KI mice. Respiratory exchange ratio (R.E.R.) time plots of chow-fed WT (C) and S108A-KI (D) treated with saline or Intralipid. Average RER (E) over 4 hrs, starting 1 hr post-gavage of saline or Intralipid (10 mL/kg). Food intake during 2 hr refeed (F) prior to, and activity levels over 1 hr,(G) starting 6 hours following, an injection of saline or AlCAR (500 mg/kg). Respiratory exchange ratio (R.E.R.) time plots of chow-fed WT (H) and S108A-KI (I) treated with saline or AlCAR. Average RER (J) over 1 hr, starting 6 hrs post-injection of saline or AlCAR. Data are means ± S.E.M. White circles are individual mice per group.



Supplemental Figure 5. Other markers of mitophagy are not altered with palmitate treatment or S108A-KI in primary hepatocytes from mice. Representative immunoblotting (A) and densitometrical analysis of P62 (B) BNIP3 (C), NIX (D), CISD1 (E) assessing mitophagy in response to palmitate ( $500\,\mu\text{M}$ ) in primary hepatocytes from CD-fed WT and S108A-KI mice. Data are means  $\pm$  S.E.M. and white circles are technical replicates from experiments from 3 experimental replicates per group. Grey bar equals a WT difference and blue bar equals to a S108A-KI difference. Statistical significance was accepted at p < 0.05 and determined via repeated-measures two-way ANOVA with Tukey's posthoc analysis.

## SI References

1. M. J. Sanders, *et al.*, Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. *J. Biol. Chem.* **282**, 32539–32548 (2007).